Thomson Reuters Corp.

Information services

Adaptimmune Therapeutics Announces FDA Acceptance of IND for MAGE-A10 T Therapeutic Candidate in Non-Small Cell Lung Cancer

Adaptimmune Therapeutics, a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products, has announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors (TCRs) specific for MAGE A10